Paul Nghiem

Paul Nghiem is the world's leading expert on Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine skin cancer. His laboratory discovered key aspects of Merkel cell polyomavirus oncogenesis and has pioneered immunotherapy approaches for MCC. He led pivotal clinical trials demonstrating that pembrolizumab and avelumab produce durable responses in MCC patients. He maintains the largest MCC patient registry globally and has developed the most widely used staging system and treatment guidelines for this disease.